Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ943MR)

This product GTTS-WQ943MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ943MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5675MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ6249MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CR57
GTTS-WQ12436MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ3634MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ12929MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ15850MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ15866MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ5077MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAM-3001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW